Data updated: May 26, 2026
ETICOVO (etanercept-ykro)
Immunology
Approved 2019-04-25
2
Indications
--
Phase 3 Trials
7
Years on Market
Details
- Status
- Prescription
- First Approved
- 2019-04-25
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ETICOVO Approval History
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
8 FDA actions from 2019 to 2025 · 1 indication expansions
What ETICOVO Treats
2 FDA approvalsOriginally approved for its first indication in 2019 . Covers 2 distinct patient populations.
- Other (2)
Pharmacists can substitute ETICOVO for Enbrel without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ETICOVO FDA Label Details
Track ETICOVO with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.